The miracle cancer drug that saves lives but costs €8,086 per dose

Pembrolizumab (Keytruda) spending in Ireland rose 800% over the past decade, from €9.7 million in 2017 to €86.3 million in the first 11 months of last year, with claims increasing from 1,219 to 9,255. The article highlights access barriers, long reimbursement timelines averaging 617 days and 694 days for cancer drugs, and ongoing policy pressure over drug pricing, dosing, and biosimilar competition. MSD reported $65 billion in full-year sales, while Keytruda exclusivity is expected to expire in the US in 2028 and Europe in 2031.

Analysis

The investable signal is not the clinical value of Pembrolizumab, but the pricing and access regime around checkpoint inhibitors. The article reinforces that reimbursement friction can persist for years even after regulatory approval, which is a negative for European oncology access and a positive for manufacturers with enough pipeline breadth to absorb periodic pricing pushback. For IPHA members, the near-term read-through is mixed: the industry gets a more sympathetic political narrative, but also a higher probability of harder procurement scrutiny, forced discounts, and volume controls as systems try to cap budget impact.

The second-order effect is that this kind of public pressure accelerates substitution behavior before the patent cliff, especially in countries with centralized payers. That favors biosimilar developers, dose-optimization tools, and companies with differentiated subcutaneous delivery or combination regimens that can justify premium pricing. It is a negative for “flat-dose at scale” economics because once payers see a credible alternative dosing framework, they will push every large oncology franchise for real-world evidence and contract concessions.

The real catalyst over the next 6-18 months is reimbursement reform, not litigation or science. If the Irish 180-day commitment is enforced, it is likely to become a template for other EU markets under budget pressure; that would compress launch premium duration across oncology portfolios and modestly reduce long-dated growth assumptions for large-cap pharma. The biggest risk to the bearish payer thesis is that clinical demand keeps rising faster than policy can constrain it, so spending can still grow even if unit pricing softens.

Consensus is probably underestimating how much of Keytruda’s value is tied to operational convenience and institutional inertia rather than pure differentiation. That means the market may be too complacent on future erosion once subcutaneous alternatives, biosimilars, and dose-optimization become standard procurement talking points. The trade is not to short the whole sector; it is to fade the most reimbursement-dependent franchises and own the beneficiaries of cost containment.

Key Decisions for Investors

• Long a basket of oncology biosimilar and lower-cost biologics exposure versus short large-cap oncology incumbents over 6-12 months; best expression is a pair trade that benefits from payer pushback and patent-cliff erosion.
• Initiate a tactical short in large-cap pharma names with heavy PD-1 exposure on any strength over the next 1-3 months; risk/reward improves if EU reimbursement headlines broaden beyond Ireland.
• Add selectively to companies with subcutaneous drug-delivery/platform exposure on a 6-18 month horizon; these names can capture workflow and administration-cost savings even if drug pricing comes under pressure.
• Avoid paying up for pharma multiples until there is evidence the 180-day reimbursement promise is being operationalized; use the next two quarters as the key validation window.
• If owning IPHA, prefer a market-neutral stance and hedge with shorts in highly reimbursed oncology franchises, since the association can gain politically even as pricing power deteriorates.